Several direct meta-analyses did not detect a statistically significant difference between maximal androgen blockade and GnRH agonist monotherapy,[11] ADT (predominantly GnRH agonist) and no treatment,[12] GnRH agonist and GnRH antagonist in patients without CV disease and naïve of any cancer treatment.[13] Insufficient power and classification bias on such safety secondary outcomes prevent a definitive conclusion. The gene discussed is GNRH1; the disease is cancer.